TCWP’s Apellis Pharmaceuticals APLS Stock Holding History

TCWP’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31	Closed	-$1K	–	345
2022 Q1	$1K	Buy	+31	New	+$1.37K	﹤0.01%	1444

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCWP's APLS Position: Q2 2022 in Review

TCWP sold out of Apellis Pharmaceuticals (APLS) in Q2 2022, closing a stake of 31 shares — an estimated $1K sold.

TCWP first reported a position in APLS in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 211 funds tracked by Wall St. Rank hold APLS as of Q2 2022.

TCWP reported no remaining Apellis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TCWP sold 31 Apellis Pharmaceuticals shares in Q2 2022, an estimated $1K.
TCWP first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 1 quarter.
TCWP's Apellis Pharmaceuticals position peaked at $1K in Q1 2022.
211 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.